Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    Data Compilation
    #PharmaFlow

    Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

    Stock Recap
    #PipelineProspector

    Menu

    Anagliptin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 496,620Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    27/02/2026 JW Pharmaceutical Corporation
    South Korea
    		 JW Pharmaceutical Corporation 228MF10137 Anagliptin 2016-07-27 2023-11-29 38, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
    27/02/2026 Sekisui Medical Co., Ltd.
    Gabon
    		 Sekisui Medical Co., Ltd. 223MF10169 Anagliptin 2011-12-09 2025-10-29 2-1-3 Nihonbashi, Chuo-ku, Tokyo
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.